Scholarlink

<p>Local healers in South Asia use <i>Plumeria rubra</i> Linn. leaves to treat various coagulation disorders in animals and humans. This study (in silico, in vitro, and in vivo) aimed to explore the pharmacological basis for the possible thrombolytic and anticlotting properties of the leaf extract of <i>P. rubra.</i> Phytoconstituents of <i>P. rubra</i> were dock against coagulation proteins: prothrombin, thromboplastin, and fibrin using in silico approach. Phytochemical screening, HPLC, and antioxidant, anticoagulant, and thrombolytic potential were evaluated using in vitro approach. Healthy male rabbits were divided into five groups (six rabbits each). Groups 1–3 were treated with aqueous-methanolic (30:70%) extract of <i>P. rubra</i> at 200, 300, and 600&#xa0;mg/mL respectively groups in contrast to the positive and negative control groups. Thrombolytic activity was assessed at doses of 200, 300, and 600&#xa0;µg/mL in comparison with standard urokinase (600&#xa0;µg/kg). Platelet adhesion was evaluated at a dose of 200, 300, and 600&#xa0;µg/mL against adrenaline (2&#xa0;µM) and acute oral dose toxicity was assessed using in vivo approach. In silico study resulted in an excellent binding affinity and showed significant interaction with coagulation proteins. Phytochemical analysis showed a range of phytochemical classes: alkaloids, tannins, flavonoids, glycosides, anthraquinones, and saponins. HPLC analysis confirmed the phytoconstituents plumericin, rutin, kaempferol, and isoquercetin already reported for coagulation disorders. <i>P. rubra</i> showed excellent antioxidant potential and was assessed using DPPH, NO, and SOD assays. The activated partial thromboplastin time (APTT), bleeding time (BT), prothrombin time (PT), and clotting time (CT) all went up with increasing doses in the aqueous-methanolic extract (<i>p</i> ≤ 0.05). Comparing the plant extract to urokinase, the plant extract demonstrated considerable (<i>p</i> ≤ 0.05) clot lysis. Additionally, it dose-dependently delayed the ADR-induced platelet adhesion dose-dependently (<i>p</i> ≤ 0.05). The outcome of this study justifies its therapeutic utility in coagulation disorders and can be used as an alternative medicine.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biochemical validation for the therapeutic use of Plumeria rubra in coagulation disorders: a study combining in silico, in vitro, and in vivo approaches

  • 期刊论文

  • 发表日期：

    2025年4月21日

查看全文
  • Imran Ahmad Khan,
  • Muhammad Anwar,
  • Sarmad Frogh Arshad,
  • Athar Hussain,
  • Muhammad Usman,
  • Mohammed Nadeem Ansari,
  • Hasan Junaid Arshad,
  • Asma Shah Rukh,
  • Qurat Ul Ain,
  • Maliha Khalid Khan

摘要

Local healers in South Asia use Plumeria rubra Linn. leaves to treat various coagulation disorders in animals and humans. This study (in silico, in vitro, and in vivo) aimed to explore the pharmacological basis for the possible thrombolytic and anticlotting properties of the leaf extract of P. rubra. Phytoconstituents of P. rubra were dock against coagulation proteins: prothrombin, thromboplastin, and fibrin using in silico approach. Phytochemical screening, HPLC, and antioxidant, anticoagulant, and thrombolytic potential were evaluated using in vitro approach. Healthy male rabbits were divided into five groups (six rabbits each). Groups 1–3 were treated with aqueous-methanolic (30:70%) extract of P. rubra at 200, 300, and 600 mg/mL respectively groups in contrast to the positive and negative control groups. Thrombolytic activity was assessed at doses of 200, 300, and 600 µg/mL in comparison with standard urokinase (600 µg/kg). Platelet adhesion was evaluated at a dose of 200, 300, and 600 µg/mL against adrenaline (2 µM) and acute oral dose toxicity was assessed using in vivo approach. In silico study resulted in an excellent binding affinity and showed significant interaction with coagulation proteins. Phytochemical analysis showed a range of phytochemical classes: alkaloids, tannins, flavonoids, glycosides, anthraquinones, and saponins. HPLC analysis confirmed the phytoconstituents plumericin, rutin, kaempferol, and isoquercetin already reported for coagulation disorders. P. rubra showed excellent antioxidant potential and was assessed using DPPH, NO, and SOD assays. The activated partial thromboplastin time (APTT), bleeding time (BT), prothrombin time (PT), and clotting time (CT) all went up with increasing doses in the aqueous-methanolic extract (p ≤ 0.05). Comparing the plant extract to urokinase, the plant extract demonstrated considerable (p ≤ 0.05) clot lysis. Additionally, it dose-dependently delayed the ADR-induced platelet adhesion dose-dependently (p ≤ 0.05). The outcome of this study justifies its therapeutic utility in coagulation disorders and can be used as an alternative medicine.

Graphical abstract